Get to know our clinical trials
Phase IB, open-label, multicenter, Phase IB clinical trial to evaluate the safety, pharmacokinetics and activity of RO7496353 in patients with locally advanced or metastatic solid tumors.
THE MAIN OBJECTIVE OF THIS STUDY IS TO TEST RO7496353 IN COMBINATION WITH ATEZOLIZUMAB TO FIND OUT IF THE COMBINATION OF THE TWO DRUGS IS SAFE AND TO UNDERSTAND HOW YOUR BODY PROCESSES THEM.
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- Code EudraCT: 2022-502615-11-00
- Protocol number: GO44010
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.